Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.

Abbou SD, Shulman DS, DuBois SG, Crompton BD.

Pediatr Blood Cancer. 2019 Jan 6:e27595. doi: 10.1002/pbc.27595. [Epub ahead of print] Review.

PMID:
30614191
2.

Risk stratification by somatic mutation burden in Ewing sarcoma.

Liu KX, Lamba N, Hwang WL, Niemierko A, DuBois SG, Haas-Kogan DA.

Cancer. 2019 Jan 2. doi: 10.1002/cncr.31919. [Epub ahead of print]

PMID:
30602061
3.

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors.

Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER.

Am J Surg Pathol. 2018 Dec 24. doi: 10.1097/PAS.0000000000001203. [Epub ahead of print]

PMID:
30585824
4.

Clinical Impact of Tumor Mutational Burden in Neuroblastoma.

Hwang WL, Wolfson RL, Niemierko A, Marcus KJ, DuBois SG, Haas-Kogan D.

J Natl Cancer Inst. 2018 Oct 10. doi: 10.1093/jnci/djy157. [Epub ahead of print]

PMID:
30307503
5.

Neuroblastoma and Histone Demethylation.

DuBois SG, Park JR.

N Engl J Med. 2018 Oct 11;379(15):1476-1477. doi: 10.1056/NEJMcibr1806782. No abstract available.

PMID:
30304660
6.

Genome-Informed Targeted Therapy for Osteosarcoma.

Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu HY, Spillinger A, Shah AT, Tanasa B, Straessler K, Hazard FK, Spunt SL, Marina N, Kim GE, Cho SJ, Avedian RS, Mohler DG, Kim MO, DuBois SG, Hawkins DS, Sweet-Cordero EA.

Cancer Discov. 2019 Jan;9(1):46-63. doi: 10.1158/2159-8290.CD-17-1152. Epub 2018 Sep 28.

PMID:
30266815
7.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.

DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS.

Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.

8.
9.

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.

Br J Cancer. 2018 Aug;119(5):615-621. doi: 10.1038/s41416-018-0212-9. Epub 2018 Aug 21.

PMID:
30131550
10.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.

Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. doi: 10.1158/1078-0432.CCR-18-1381. Epub 2018 Aug 9.

PMID:
30093449
11.

Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors.

Klega K, Imamovic-Tuco A, Ha G, Clapp AN, Meyer S, Ward A, Clinton C, Nag A, Van Allen E, Mullen E, DuBois SG, Janeway K, Meyerson M, Thorner AR, Crompton BD.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00285. Epub 2018 Jul 5.

12.

Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma.

Worch J, Ranft A, DuBois SG, Paulussen M, Juergens H, Dirksen U.

Pediatr Blood Cancer. 2018 Sep;65(9):e27251. doi: 10.1002/pbc.27251. Epub 2018 Jun 1.

PMID:
29856530
13.

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA.

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

14.

Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G, Colombo C, Virgone C, DuBois SG, Gronchi A, Rossi CR, Mocellin S.

Oncotarget. 2018 Apr 6;9(26):18607-18626. doi: 10.18632/oncotarget.24719. eCollection 2018 Apr 6.

15.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.

Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Erratum in: Lancet Oncol. 2018 May;19(5):e229.

PMID:
29606586
16.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR.

Pediatr Blood Cancer. 2018 Jul;65(7):e27023. doi: 10.1002/pbc.27023. Epub 2018 Mar 30.

17.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

18.

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.

Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, Kozakewich HP, Janeway KA, Perez-Atayde AR, Harris MH.

Mod Pathol. 2018 Mar;31(3):463-473. doi: 10.1038/modpathol.2017.127. Epub 2017 Nov 3.

PMID:
29099503
19.

Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach.

Storck S, Kennedy AL, Marcus KJ, Teot L, Vaughn J, Gnekow AK, Märkl B, Leuschner I, DuBois SG, French CA, Frühwald MC.

Pediatr Hematol Oncol. 2017 May;34(4):231-237. doi: 10.1080/08880018.2017.1363839. Epub 2017 Oct 17.

PMID:
29040054
20.

Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.

Messinger Y, Boklan J, Goldberg J, DuBois SG, Oesterheld J, Abla O, Martin A, Weinstein J, Hijiya N.

Pediatr Hematol Oncol. 2017 May;34(4):187-198. doi: 10.1080/08880018.2017.1360970. Epub 2017 Oct 17.

PMID:
29039989
21.

Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.

Ahmed SK, Randall RL, DuBois SG, Harmsen WS, Krailo M, Marcus KJ, Janeway KA, Geller DS, Sorger JI, Womer RB, Granowetter L, Grier HE, Gorlick RG, Laack NNI.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1286-1294. doi: 10.1016/j.ijrobp.2017.08.020. Epub 2017 Aug 24.

22.

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):468-475. doi: 10.1016/j.ijrobp.2017.05.008. Epub 2017 May 15.

PMID:
28871998
23.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG.

Cancer. 2017 Nov 1;123(21):4224-4235. doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

24.

Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma.

Gauguet JM, Pace-Emerson T, Grant FD, Shusterman S, DuBois SG, Frazier AL, Voss SD.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26601. Epub 2017 Apr 27.

PMID:
28449267
25.

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN.

Clin Cancer Res. 2017 May 15;23(10):2433-2441. doi: 10.1158/1078-0432.CCR-16-2898. Epub 2017 Apr 21.

26.

MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

DuBois SG, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D, Kreissman S, Baker DL, Parisi M, Shulkin BL, Bai H, Diskin SJ, Batra V, Maris JM, Park JR, Matthay KK, Yanik G.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26545. Epub 2017 Apr 6.

27.

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma.

Cash T, Yin H, McCracken C, Geng Z, DuBois SG, Shehata BM, Olson TA, Katzenstein HM, Wetmore C.

Sarcoma. 2017;2017:8758623. doi: 10.1155/2017/8758623. Epub 2017 Jan 26.

28.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
29.

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L.

J Clin Oncol. 2016 Dec 20;34(36):4381-4389. Epub 2016 Oct 31.

PMID:
27998223
30.

Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma.

Dinh T, Truong B, Matthay KK, DuBois SG.

J Pediatr Hematol Oncol. 2017 Mar;39(2):108-113. doi: 10.1097/MPH.0000000000000692.

PMID:
27820129
31.

Assessment of Chemotherapy Response in Ewing Sarcoma: Response

Daldrup-Link HE, DuBois SG, Aghighi M, Marina N, Petit P.

Radiology. 2016 Nov;281(2):647-649. doi: 10.1148/radiol.2016160903. No abstract available.

PMID:
29672009
32.

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.

Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG.

Oncotarget. 2017 Apr 4;8(14):23851-23861. doi: 10.18632/oncotarget.12904.

33.

Editors' Note.

DuBois JM, Iltis AS, DuBois SG.

Narrat Inq Bioeth. 2016;6(2):v. No abstract available.

PMID:
27763384
34.

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.

Pearson AD, Federico SM, Aerts I, Hargrave DR, DuBois SG, Iannone R, Geschwindt RD, Wang R, Haluska FG, Trippett TM, Geoerger B.

Oncotarget. 2016 Dec 20;7(51):84736-84747. doi: 10.18632/oncotarget.12450.

35.

Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.

Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, Smirnoff IV, Horvai AE, Loh M, DuBois SG, Goldsby RE, Neglia JP, Hammond S, Robison LL, Wustrack R, Costello JF, Nakamura AO, Shannon KM, Bhatia S, Nakamura JL.

Clin Cancer Res. 2017 Apr 1;23(7):1852-1861. doi: 10.1158/1078-0432.CCR-16-0610. Epub 2016 Sep 28.

36.

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK.

Eur J Cancer. 2016 Oct;66:144-52. doi: 10.1016/j.ejca.2016.07.017. Epub 2016 Aug 27.

PMID:
27573428
37.

Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.

Edmondson DA, Karski EE, Kohlgruber A, Koneru H, Matthay KK, Allen S, Hartmann CL, Peterson LE, DuBois SG, Coleman MA.

Radiat Res. 2016 Sep;186(3):235-44. doi: 10.1667/RR14263.1. Epub 2016 Aug 24.

38.

Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience.

Marron JM, DuBois SG, Glade Bender J, Kim A, Crompton BD, Meyer SC, Janeway KA, Mack JW.

Pediatr Blood Cancer. 2016 Nov;63(11):1974-82. doi: 10.1002/pbc.26137. Epub 2016 Jul 18.

39.

Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?

Lee JS, Matthay K, DuBois SG, Roy-Burman A.

Pediatr Blood Cancer. 2016 Oct;63(10):1868. doi: 10.1002/pbc.26078. Epub 2016 Jul 9. No abstract available.

PMID:
27394054
40.

Editors' Note.

DuBois JM, Ilitis AS, DuBois SG.

Narrat Inq Bioeth. 2016;6(1):v. doi: 10.1353/nib.2016.0007. No abstract available.

PMID:
27346826
41.

Introduction: Political Influence on Bioethical Deliberation.

DuBois JM, Iltis AS, DuBois SG.

Narrat Inq Bioeth. 2016;6(1):1-3. doi: 10.1353/nib.2016.0001.

PMID:
27346808
42.

Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.

Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, Sorger J, Marina N, Grier HE, Granowetter L, Womer RB, DuBois SG.

Pediatr Blood Cancer. 2016 Oct;63(10):1771-9. doi: 10.1002/pbc.26096. Epub 2016 Jun 14.

43.

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.

Vo KT, Matthay KK, DuBois SG.

Clin Sarcoma Res. 2016 Jun 7;6:9. doi: 10.1186/s13569-016-0049-z. eCollection 2016. Review.

44.

Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.

Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B.

Eur J Cancer. 2016 Jul;62:9-17. doi: 10.1016/j.ejca.2016.03.084. Epub 2016 May 10.

PMID:
27185573
45.

Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor.

Bent MA, Padilla BE, Goldsby RE, DuBois SG.

Rare Tumors. 2016 Apr 1;8(1):6145. doi: 10.4081/rt.2016.6145. eCollection 2016 Mar 21.

46.

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR.

Cancer Genet. 2016 May;209(5):182-94. doi: 10.1016/j.cancergen.2016.03.004. Epub 2016 Apr 5. Review.

47.

Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1396. No abstract available.

PMID:
27044383
48.

Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE.

Radiology. 2016 Sep;280(3):905-15. doi: 10.1148/radiol.2016151301. Epub 2016 Mar 16.

49.

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA.

Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26.

50.

Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma.

Davenport JR, Vo KT, Goldsby R, West DC, DuBois SG.

Pediatr Blood Cancer. 2016 Jun;63(6):1091-5. doi: 10.1002/pbc.25945. Epub 2016 Feb 17.

PMID:
26891183

Supplemental Content

Loading ...
Support Center